SIStockInvestingSI.com

NYSE · ABT · Medical Devices

Abbott Laboratories (ABT) stock analysis

$100.51−1.89%Data as of Oct 21, 2026
  • ABT lost 3.1% over the past month versus 0.0% for the S&P 500, ranking 372nd of 497 S&P 500 stocks.
  • Over 12 months it returned −21.5%, 37.3 points behind the S&P 500, and trades 22.2% below its 52-week high.
  • In the last 30 days 1 analyst raised earnings estimates and 1 cut; forward EPS moved 0.0% (+0.2% over 90 days).
  • It sits in the Diagnostics, monitoring & imaging segment of the Healthcare Value Chain, where the 1-month median return is −3.1%.
  • The daily chart reads Trend transition · Unresolved structure (since Oct 21, 2026).
Market cap$173.9B
12-month return−21.5%
Forward P/E16.6×
Mean target vs price+20.1%

One-year price with 50- and 200-day averages

Open in Hub
86.5100114128JanAprJulOct
100.5150-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

ABT−3.1%
Sector median−8.7%
S&P 5000.0%
ABT−0.2%
Sector median−5.4%
S&P 500+4.7%
ABT+9.6%
Sector median−1.5%
S&P 500+8.7%
ABT−21.5%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 500372 / 497
3-month rank in its sector · Healthcare309 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Trend transition · Unresolved structureAwaiting confirmation

Holding since Oct 21, 2026

  • Close below EMA20 below EMA50
  • EMA50 is approximately flat
  • Confirmed swing highs and lows are rising
  • Volume exceeds 1.5× the prior 20-session average; supporting evidence only
  • Intermediate and long-term directions differ
  • Neither a stable trend nor a range is confirmed
This pattern on this stock

86 occurrences in 10 years. The median move over the next 20 sessions was +2.4%, positive 63% of the time, against +0.9% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$6.07
30-day change0.0%
90-day change+0.2%
Mean target$120.72 +20.1%
Raised (30d) 1Cut (30d) 1

26 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Ahead of peersRevisions

Behind peersGrowth, Profit

PeersMDT · SYK · BSX · EW

Where it sits in the supply chain

Healthcare Value Chain · Drugs & devices

Explore the full chain map in Hub
Its segment
Diagnostics, monitoring & imaging−3.1%
ABT−3.1%1 monthDXCM−10.4%1 monthGEHC+4.1%1 month

Continuous glucose monitors, diagnostics and imaging; the spread of GLP-1 drugs raised concern about diabetes-device demand.

Sells into
Hospitals & care delivery+8.4%
HCA+4.9%1 monthUNH+11.8%1 month
PBMs & pharmacies+9.3%
CVS+7.3%1 monthCI+11.2%1 monthUNH+11.8%1 month6618.HK+7.3%1 month

Also on: Medtech, Diagnostics & Care

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−36.1%
Volatility, 60D21.7%
From 52-week high−22.2%
From 52-week low+21.7%
Trailing P/E32.3×
Forward P/E16.6×

Themes

  • MedTech3M rank 49 / 90
DXCMDexCom, Inc.UNHUnitedHealth GroupCVSCVS HealthCICignaMDTMedtronicSYKStrykerBSXBoston ScientificEWEdwards Lifesciences Corporatio

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗